Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 3Tumor-Agnostic 2Genitourinary 2Dermatologic 2Thoracic 1Sarcoma 1Head & Neck 1CNS 1Breast 1

Conditions

Neoplasms 3Neoplasm Metastasis 3Carcinoma 2Neoplasm, Residual 1

Interventions

Paclitaxel 9Carboplatin 9pembrolizumab 7Radiotherapy 7Cisplatin 5Axitinib 4Pemetrexed 3Nivolumab 3trifluridine tipiracil drug combination 2regorafenib 2osimertinib 2fludarabine 2dacomitinib 2catumaxomab 2Trastuzumab 2Sunitinib 2Radiotherapy, Intensity-Modulated 2Nurses 2Interleukin-2 2Gemcitabine 2Docetaxel 2Cyclophosphamide 2Cetuximab 2Bevacizumab 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2vatalanib 1temsirolimus 1sovateltide 1selinexor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma × fludarabine × Tumor-Agnostic × Clear all
NCT05141474 2024-11-07

NEXTGENTIL-ACT

Vall d'Hebron Institute of Oncology

Phase EARLY_PHASE1 Recruiting
10 enrolled
Tumor-Agnostic

Carcinoma

NCT06013111 2024-02-21

An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CEA-CAR-T Cells Injection in Patients With CEA+ Locally Advanced and/or Metastatic Solid Tumors

China Medical University, China

Phase 1 Recruiting
9 enrolled
Tumor-Agnostic

Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡